US › Healthcare

Orchestra BioMed Holdings Inc. (OBIO)

US · Healthcare · Biotechnology

$5.78-3.83%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$88,000

Revenue YoY

-89.5%

Net profit

$-23.8M

EPS

$-0.38

EPS estimate

$-0.35

Net margin

-26,994.3%

EPS came in at -0.38 against a street estimate of -0.35 — a miss of 8.6%.

Key statistics

Market cap

$361.2M

Forward P/E

0.0

P/B

18.79

Book value

$0.32

EPS (TTM)

$-0.84

52-week high

$6.28

52-week low

$2.20

50-day MA

$4.56

200-day MA

$4.31

Beta

0.53

Analyst view

Analysts rate Orchestra BioMed Holdings Inc. a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $12.00.

Shareholding

Insiders

24.45%

Institutions

47.66%

Largest institutional holders

Fund	Stake
RTW INVESTMENTS, LLC	13.82%
Perceptive Advisors LLC	8.38%
Vanguard Capital Management, LLC	3.67%
Alyeska Investment Group, L.P.	1.66%
Propel Bio Management LLC	1.49%
BlackRock Inc	1.06%
Geode Capital Management, LLC	0.81%
Rice Hall James & Associates, LLC	0.71%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Orchestra BioMed Holdings Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.